Brind.

Neurocrine Biosciences presented at a TD Cowen summit in August 2025.

1 report, 1 independent Updated Aug 27

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Neurocrine Biosciences TD Cowen

Keep exploring

The entities involved

Neurocrine Biosciences
American biopharmaceutical company

Nothing else this week.
TD Cowen
American investment bank
- Analyst downgraded Ag Growth International Inc. due to debt management risks.Mon 12:33
- TD Cowen raised its price target and gave a buy rating for Travere Therapeutics, Inc., while various institutional investors bought into the company.Mon 10:36

Coverage

Newest first; wire copies grouped

Aug 27PR NewswireNeurocrine Biosciences to Present at Upcoming Investor Conferences in September SAN DIEGO, Aug. 26, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at four investor